Copenhagen, Denmark; June 30, 2008 – Genmab A/S (OMX: GEN) announced today it has reached a development milestone for ofatumumab (HuMax-CD20®) under the terms of its collaboration with GlaxoSmithKline (GSK).  A milestone payment of approximately DKK 29 million (approximately USD 6 million) was triggered by treatment of the first patient participating in the Phase II study of ofatumumab for the treatment of relapsing remitting multiple sclerosis (RRMS). 

“Our collaboration with GSK continues to progress as both companies work towards providing new treatment options for patients,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.  “We are pleased to begin treating patients in the first study of ofatumumab in RRMS, an unpredictable and debilitating disease.”

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a distinct small loop epitope on the CD20 receptor on the surface of B-cells.  This epitope is different from the other anti-CD20 antibodies currently available or in development.  Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GSK.